# A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

> **NCT02573324** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 691 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma

## Interventions

- **DRUG:** Temozolomide
- **DRUG:** Depatuxizumab mafodotin
- **RADIATION:** Radiation
- **DRUG:** Placebo for ABT-414

## Key facts

- **NCT ID:** NCT02573324
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-04
- **Primary completion:** 2022-04-04
- **Final completion:** 2022-04-04
- **Target enrollment:** 691 (ACTUAL)
- **Last updated:** 2023-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02573324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02573324, "A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02573324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*